Panitumumab is an anticancer drug used to treat colorectal cancer. It works by binding to and blocking a protein involved in cancer growth called the epidermal growth factor receptor (EGFR). In this study, researchers want to evaluate the safety and effectiveness of giving the investigational drug MEK162 in combination with panitumumab in several groups of patients with metastatic colorectal cancer, including patients whose tumors previously responded to panitumumab or cetuximab (another EGFR inhibitor) and then later started to grow again.
MEK162 works by inhibiting MEK1/2, a protein which drives cancer growth. Panitumumab MEK162 is taken orally (by mouth), while panitumumab is given intravenously (by vein).